Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - AccuredReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Inventory (2025)

Crinetics Pharmaceuticals has reported Inventory over the past 1 years, most recently at $2.0 million for Q4 2025.

  • For Q4 2025, Inventory changed N/A year-over-year to $2.0 million; the TTM value through Dec 2025 reached $2.0 million, changed N/A, while the annual FY2025 figure was $2.0 million, N/A changed from the prior year.
  • Inventory for Q4 2025 was $2.0 million at Crinetics Pharmaceuticals.
  • Over five years, Inventory peaked at $2.0 million in Q4 2025 and troughed at $2.0 million in Q4 2025.